N Ballardini1,2, A Bergström1, C-F Wahlgren3, M van Hage4, E Hallner1, I Kull1,5, E Melén1,2, J M Antó6,7,8,9, J Bousquet10, M Wickman1,2. 1. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Sachs' Children and Youth Hospital, South General Hospital, Stockholm, Sweden. 3. Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden. 4. Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. 5. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. 6. Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. 7. IMIM (Hospital del Mar Research Institute), Barcelona, Spain. 8. Universitat Pompeu Fabra (UPF), Barcelona, Spain. 9. CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 10. Department of Allergy and Respiratory Diseases, University Hospital and INSERM, Montpellier, France.
Abstract
BACKGROUND: Eczema, asthma, and rhinitis affect a large proportion of children, but their prevalence varies with age. IgE antibodies are also common in the pediatric population. However, the links between IgE, disease, and trajectories are unclear. OBJECTIVE: To better understand the links between sensitization and disease, we studied IgE sensitization ever in relation to eczema, asthma, and rhinitis, in children followed up to 16 years of age. METHODS: From the Swedish population-based birth cohort BAMSE, 2607 children were included. Parental reports from six time points between 1 and 16 years were used to identify children with eczema, asthma, and rhinitis. Blood was collected at 4, 8, and 16 years, and sensitization ever was defined as allergen-specific IgE ≥0.35 kUA /l to common food and/or inhalant allergens at any time point. Odds ratios for eczema, asthma, rhinitis, and multimorbidity in relation to sensitization ever were calculated using generalized estimating equations. RESULTS: Fifty-one percent were sensitized at least once up to 16 years. Almost a quarter of ever-sensitized children did not have any disease. After adjustment for potential confounders, sensitization ever was significantly associated with the following: (i) eczema throughout childhood, (ii) multimorbidity of eczema, asthma, and rhinitis from 1 to 16 years (OR for multimorbidity: 5.11, 95% CI: 3.99-6.55), (iii) asthma and rhinitis from 4 to 16 years of age. CONCLUSIONS: Specific IgE is strongly associated with eczema and allergic multimorbidity throughout childhood and with asthma and rhinitis from age 4 years. However, 23% of the children with IgE sensitization do not develop any disease in childhood.
BACKGROUND:Eczema, asthma, and rhinitis affect a large proportion of children, but their prevalence varies with age. IgE antibodies are also common in the pediatric population. However, the links between IgE, disease, and trajectories are unclear. OBJECTIVE: To better understand the links between sensitization and disease, we studied IgE sensitization ever in relation to eczema, asthma, and rhinitis, in children followed up to 16 years of age. METHODS: From the Swedish population-based birth cohort BAMSE, 2607 children were included. Parental reports from six time points between 1 and 16 years were used to identify children with eczema, asthma, and rhinitis. Blood was collected at 4, 8, and 16 years, and sensitization ever was defined as allergen-specific IgE ≥0.35 kUA /l to common food and/or inhalant allergens at any time point. Odds ratios for eczema, asthma, rhinitis, and multimorbidity in relation to sensitization ever were calculated using generalized estimating equations. RESULTS: Fifty-one percent were sensitized at least once up to 16 years. Almost a quarter of ever-sensitized children did not have any disease. After adjustment for potential confounders, sensitization ever was significantly associated with the following: (i) eczema throughout childhood, (ii) multimorbidity of eczema, asthma, and rhinitis from 1 to 16 years (OR for multimorbidity: 5.11, 95% CI: 3.99-6.55), (iii) asthma and rhinitis from 4 to 16 years of age. CONCLUSIONS: Specific IgE is strongly associated with eczema and allergic multimorbidity throughout childhood and with asthma and rhinitis from age 4 years. However, 23% of the children with IgE sensitization do not develop any disease in childhood.
Authors: Hyung-Geun Moon; Seung-Jae Kim; Myoung Kyu Lee; Homan Kang; Hak Soo Choi; Anantha Harijith; Jinhong Ren; Viswanathan Natarajan; John W Christman; Steven J Ackerman; Gye Young Park Journal: Allergy Date: 2019-10-11 Impact factor: 13.146
Authors: Anastasia Filiou; Idun Holmdahl; Anna Asarnoj; Marianne van Hage; Tina Ekenkrantz; Niclas Rydell; Anders Sjölander; Katarina Stenberg-Hammar; Gunilla Hedlin; Jon R Konradsen; Cilla Söderhäll Journal: Int Arch Allergy Immunol Date: 2022-01-18 Impact factor: 3.767
Authors: M A Calderon; P Demoly; T Casale; C A Akdis; C Bachert; M Bewick; B M Bilò; B Bohle; S Bonini; A Bush; D P Caimmi; G W Canonica; V Cardona; A M Chiriac; L Cox; A Custovic; F De Blay; P Devillier; A Didier; G Di Lorenzo; G Du Toit; S R Durham; P Eng; A Fiocchi; A T Fox; R Gerth van Wijk; R M Gomez; T Haathela; S Halken; P W Hellings; L Jacobsen; J Just; L K Tanno; J Kleine-Tebbe; L Klimek; E F Knol; P Kuna; D E Larenas-Linnemann; A Linneberg; M Matricardi; H J Malling; R Moesges; J Mullol; A Muraro; N Papadopoulos; G Passalacqua; E Pastorello; O Pfaar; D Price; P Rodriguez Del Rio; R Ruëff; B Samolinski; G K Scadding; G Senti; M H Shamji; A Sheikh; J C Sisul; D Sole; G J Sturm; A Tabar; R Van Ree; M T Ventura; C Vidal; E M Varga; M Worm; T Zuberbier; J Bousquet Journal: Clin Transl Allergy Date: 2016-11-23 Impact factor: 5.871
Authors: J Bousquet; P W Hellings; I Agache; A Bedbrook; C Bachert; K C Bergmann; M Bewick; C Bindslev-Jensen; S Bosnic-Anticevitch; C Bucca; D P Caimmi; P A M Camargos; G W Canonica; T Casale; N H Chavannes; A A Cruz; G De Carlo; R Dahl; P Demoly; P Devillier; J Fonseca; W J Fokkens; N A Guldemond; T Haahtela; M Illario; J Just; T Keil; L Klimek; P Kuna; D Larenas-Linnemann; M Morais-Almeida; J Mullol; R Murray; R Naclerio; R E O'Hehir; N G Papadopoulos; R Pawankar; P Potter; D Ryan; B Samolinski; H J Schunemann; A Sheikh; F E R Simons; C Stellato; A Todo-Bom; P V Tomazic; A Valiulis; E Valovirta; M T Ventura; M Wickman; I Young; A Yorgancioglu; T Zuberbier; W Aberer; C A Akdis; M Akdis; I Annesi-Maesano; J Ankri; I J Ansotegui; J M Anto; S Arnavielhe; A Asarnoj; H Arshad; F Avolio; I Baiardini; C Barbara; M Barbagallo; E D Bateman; B Beghé; E H Bel; K S Bennoor; M Benson; A Z Białoszewski; T Bieber; L Bjermer; H Blain; F Blasi; A L Boner; M Bonini; S Bonini; I Bosse; J Bouchard; L P Boulet; R Bourret; P J Bousquet; F Braido; A H Briggs; C E Brightling; J Brozek; R Buhl; C Bunu; E Burte; A Bush; F Caballero-Fonseca; M A Calderon; T Camuzat; V Cardona; P Carreiro-Martins; A M Carriazo; K H Carlsen; W Carr; A M Cepeda Sarabia; M Cesari; L Chatzi; R Chiron; T Chivato; E Chkhartishvili; A G Chuchalin; K F Chung; G Ciprandi; J Correia de Sousa; L Cox; G Crooks; A Custovic; S E Dahlen; U Darsow; T Dedeu; D Deleanu; J A Denburg; G De Vries; A Didier; A T Dinh-Xuan; D Dokic; H Douagui; G Dray; R Dubakiene; S R Durham; G Du Toit; M S Dykewicz; P Eklund; Y El-Gamal; E Ellers; R Emuzyte; J Farrell; A Fink Wagner; A Fiocchi; M Fletcher; F Forastiere; M Gaga; A Gamkrelidze; B Gemicioğlu; J E Gereda; R Gerth van Wick; S González Diaz; I Grisle; L Grouse; Z Gutter; M A Guzmán; B Hellquist-Dahl; J Heinrich; F Horak; J O' B Hourihane; M Humbert; M Hyland; G Iaccarino; E J Jares; C Jeandel; S L Johnston; G Joos; O Jonquet; K S Jung; M Jutel; I Kaidashev; M Khaitov; O Kalayci; A F Kalyoncu; P Kardas; P K Keith; M Kerkhof; H A M Kerstjens; N Khaltaev; M Kogevinas; V Kolek; G H Koppelman; M L Kowalski; M Kuitunen; I Kull; V Kvedariene; B Lambrecht; S Lau; D Laune; L T T Le; P Lieberman; B Lipworth; J Li; K C Lodrup Carlsen; R Louis; C Lupinek; W MacNee; Y Magar; A Magnan; B Mahboub; D Maier; I Majer; J Malva; P Manning; E De Manuel Keenoy; G D Marshall; M R Masjedi; E Mathieu-Dupas; M Maurer; S Mavale-Manuel; E Melén; E Melo-Gomes; E O Meltzer; J Mercier; H Merk; N Miculinic; F Mihaltan; B Milenkovic; J Millot-Keurinck; Y Mohammad; I Momas; R Mösges; A Muraro; L Namazova-Baranova; R Nadif; H Neffen; K Nekam; A Nieto; B Niggemann; L Nogueira-Silva; M Nogues; T D Nyembue; K Ohta; Y Okamoto; K Okubo; M Olive-Elias; S Ouedraogo; P Paggiaro; I Pali-Schöll; S Palkonen; P Panzner; A Papi; H S Park; G Passalacqua; S Pedersen; A M Pereira; O Pfaar; R Picard; B Pigearias; I Pin; D Plavec; W Pohl; T A Popov; F Portejoie; D Postma; L K Poulsen; D Price; K F Rabe; F Raciborski; G Roberts; C Robalo-Cordeiro; F Rodenas; L Rodriguez-Mañas; C Rolland; M Roman Rodriguez; A Romano; J Rosado-Pinto; N Rosario; M Rottem; M Sanchez-Borges; J Sastre-Dominguez; G K Scadding; N Scichilone; P Schmid-Grendelmeier; E Serrano; M Shields; V Siroux; J C Sisul; I Skrindo; H A Smit; D Solé; T Sooronbaev; O Spranger; R Stelmach; P J Sterk; T Strandberg; J Sunyer; C Thijs; M Triggiani; R Valenta; A Valero; M van Eerd; E van Ganse; M van Hague; O Vandenplas; L L Varona; B Vellas; G Vezzani; T Vazankari; G Viegi; T Vontetsianos; M Wagenmann; S Walker; D Y Wang; U Wahn; T Werfel; B Whalley; D M Williams; S Williams; N Wilson; J Wright; B P Yawn; P K Yiallouros; O M Yusuf; A Zaidi; H J Zar; M E Zernotti; L Zhang; N Zhong; M Zidarn Journal: Clin Transl Allergy Date: 2016-12-30 Impact factor: 5.871
Authors: J Bousquet; J M Anto; M Akdis; C Auffray; T Keil; I Momas; D S Postma; R Valenta; M Wickman; A Cambon-Thomsen; T Haahtela; B N Lambrecht; K C Lodrup Carlsen; G H Koppelman; J Sunyer; T Zuberbier; I Annesi-Maesano; A Arno; C Bindslev-Jensen; G De Carlo; F Forastiere; J Heinrich; M L Kowalski; D Maier; E Melén; S Palkonen; H A Smit; M Standl; J Wright; A Asarnoj; M Benet; N Ballardini; J Garcia-Aymerich; U Gehring; S Guerra; C Hohman; I Kull; C Lupinek; M Pinart; I Skrindo; M Westman; D Smagghe; C Akdis; R Albang; V Anastasova; N Anderson; C Bachert; S Ballereau; F Ballester; X Basagana; A Bedbrook; A Bergstrom; A von Berg; B Brunekreef; E Burte; K H Carlsen; L Chatzi; J M Coquet; M Curin; P Demoly; E Eller; M P Fantini; B Gerhard; H Hammad; L von Hertzen; V Hovland; B Jacquemin; J Just; T Keller; M Kerkhof; R Kiss; M Kogevinas; S Koletzko; S Lau; I Lehmann; N Lemonnier; R McEachan; M Mäkelä; J Mestres; E Minina; P Mowinckel; R Nadif; M Nawijn; S Oddie; J Pellet; I Pin; D Porta; F Rancière; A Rial-Sebbag; Y Saeys; M J Schuijs; V Siroux; C G Tischer; M Torrent; R Varraso; J De Vocht; K Wenger; S Wieser; C Xu Journal: Allergy Date: 2016-08-23 Impact factor: 13.146
Authors: T Keller; C Hohmann; M Standl; A H Wijga; U Gehring; E Melén; C Almqvist; S Lau; E Eller; U Wahn; E S Christiansen; A von Berg; J Heinrich; I Lehmann; D Maier; D S Postma; J M Antó; J Bousquet; T Keil; S Roll Journal: Allergy Date: 2017-11-07 Impact factor: 13.146